title: Single-joint Assessment for the Evaluation of Intraarticular Treatment: Responsiveness and Discrimination of the Composite Change Index.
abstract: OBJECTIVE
  To investigate responsiveness, discrimination, and construct validity of a composite change index (CCI) for the assessment of single-joint involvement in inflammatory arthritis.
  
  
  METHODS
  Evaluation of standardized response means (SRM), Guyatt effect size, and Spearman rank correlation coefficient in a randomized controlled trial investigating the effect of an intraarticular etanercept injection.
  
  
  RESULTS
  The CCI showed a high SRM (1.68) and high Guyatt effect size (2.72). Both visual analog scale of pain and functionality had a moderate Guyatt effect size (2.06, 2.44) and high SRM (0.81, 0.97).
  
  
  CONCLUSIONS
  This study supports the use of the CCI as a single-joint assessment after single-joint intervention.
  
  
  BACKGROUND
  NTR-1210.
authors.affiliation: From the Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam; Arthrogen B.V., Amsterdam; Department of Rheumatology, Atrium Medical Center, Heerlen, the Netherlands.C.J. Aalbers, MD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, and Arthrogen B.V.; D.M. Gerlag, MD, PhD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam; M.J. Vervoordeldonk, PhD, Arthrogen B.V.; P.P. Tak, MD, PhD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, and Arthrogen B.V., and GlaxoSmithKline, and University of Cambridge; R.B. Landewé, MD, PhD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, and Department of Rheumatology, Atrium Medical Center. c.j.aalbers@amc.uva.nl.
authors.forename: Caroline J
authors.initials: CJ
authors.lastname: Aalbers
authors.affiliation: From the Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam; Arthrogen B.V., Amsterdam; Department of Rheumatology, Atrium Medical Center, Heerlen, the Netherlands.C.J. Aalbers, MD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, and Arthrogen B.V.; D.M. Gerlag, MD, PhD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam; M.J. Vervoordeldonk, PhD, Arthrogen B.V.; P.P. Tak, MD, PhD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, and Arthrogen B.V., and GlaxoSmithKline, and University of Cambridge; R.B. Landewé, MD, PhD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, and Department of Rheumatology, Atrium Medical Center.
authors.forename: Danielle M
authors.initials: DM
authors.lastname: Gerlag
authors.affiliation: From the Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam; Arthrogen B.V., Amsterdam; Department of Rheumatology, Atrium Medical Center, Heerlen, the Netherlands.C.J. Aalbers, MD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, and Arthrogen B.V.; D.M. Gerlag, MD, PhD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam; M.J. Vervoordeldonk, PhD, Arthrogen B.V.; P.P. Tak, MD, PhD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, and Arthrogen B.V., and GlaxoSmithKline, and University of Cambridge; R.B. Landewé, MD, PhD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, and Department of Rheumatology, Atrium Medical Center.
authors.forename: Margriet J
authors.initials: MJ
authors.lastname: Vervoordeldonk
authors.affiliation: From the Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam; Arthrogen B.V., Amsterdam; Department of Rheumatology, Atrium Medical Center, Heerlen, the Netherlands.C.J. Aalbers, MD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, and Arthrogen B.V.; D.M. Gerlag, MD, PhD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam; M.J. Vervoordeldonk, PhD, Arthrogen B.V.; P.P. Tak, MD, PhD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, and Arthrogen B.V., and GlaxoSmithKline, and University of Cambridge; R.B. Landewé, MD, PhD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, and Department of Rheumatology, Atrium Medical Center.
authors.forename: Paul P
authors.initials: PP
authors.lastname: Tak
authors.affiliation: From the Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam; Arthrogen B.V., Amsterdam; Department of Rheumatology, Atrium Medical Center, Heerlen, the Netherlands.C.J. Aalbers, MD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, and Arthrogen B.V.; D.M. Gerlag, MD, PhD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam; M.J. Vervoordeldonk, PhD, Arthrogen B.V.; P.P. Tak, MD, PhD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, and Arthrogen B.V., and GlaxoSmithKline, and University of Cambridge; R.B. Landewé, MD, PhD, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, and Department of Rheumatology, Atrium Medical Center.
authors.forename: Robert B
authors.initials: RB
authors.lastname: Landewé
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000473:pathology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology; D004185:Disability Evaluation; D004311:Double-Blind Method; D000068800:Etanercept / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007270:Injections, Intra-Articular; D007719:Knee Joint / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D000068800:Etanercept
keywords: KNEE JOINT; OUTCOME ASSESSMENT; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; TUMOR NECROSIS FACTOR INHIBITORS